Astellas Pharma Reports 16 Billion Yen US Sales of Izervay in Q1

Astellas Pharma reported 16 billion yen in US sales of Izervay for fiscal Q1. The Japan-based company primarily operates in the pharmaceutical products business segment, with main products including XTANDI, BETANIS, MIRABETRIC, BETMIGA, ZOSPATA, EVERENZO, and ENHOLTUMAB VEDOTIN.

President Donald Trump has announced that imported pharmaceutical products could face 200% tariffs, according to multiple reports. The president, speaking at a cabinet meeting on Tuesday, stated that he would provide the industry with a grace period of about a year to adjust their supply chains. This announcement comes amidst ongoing discussions about sector-specific levies on pharmaceutical imports [1].

Leerink Partners, an investment research firm, described the delay as a "positive" for the biopharma sector, noting that tariffs are not expected to be implemented immediately and it remains uncertain whether the administration will follow through [1]. The S&P Biotech ETF maintained its price at around $85, indicating minimal market reaction to the news.

Trump's threats of pharma tariffs date back to his second term, with initial discussions in February and escalating threats in April. In February, the president warned industry leaders, including Merck and Pfizer executives, that he would impose tariffs if they did not move manufacturing to the U.S. [1]. In April, Trump's Department of Commerce initiated a Section 232 national security investigation into imported pharmaceutical products [1].

Companies have responded to these threats by increasing investments in U.S.-based manufacturing. For instance, Sanofi announced a $20 billion domestic package in May 2025, aiming to create high-paying jobs in the country [1]. Other major pharmaceutical companies, such as Eli Lilly, Johnson & Johnson, Novartis, and Bristol Myers Squibb, have also made significant investments in the U.S. [1].

In a separate development, Astellas Pharma reported 16 billion yen in U.S. sales of Izervay for fiscal Q1. The Japan-based company operates primarily in the pharmaceutical products business segment, with key products including XTANDI, BETANIS, MIRABETRIC, BETMIGA, ZOSPATA, EVERENZO, and ENHOLTUMAB VEDOTIN [2].

References:
[1] https://www.biospace.com/policy/trump-threatens-200-pharma-tariffs-but-gives-at-least-1-year-grace-period
[2] Astellas Pharma Q1 Sales Report